3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Phase NA
1
Phase EARLY_PHASE1
1
Phase 2
1
Status
Unknown
9
Recruiting
9
Completed
8
Withdrawn
3
Not yet recruiting
3
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Breast Neoplasms
184
Carcinoma, Non-Small-Cell Lung
142
Multiple Myeloma
119
Prostatic Neoplasms
116
Colorectal Neoplasms
75
Leukemia, Myeloid, Acute
74
Neoplasms
73
Melanoma
71
Squamous Cell Carcinoma of Head and Neck
65
Lymphoma
64
Lung Neoplasms
64
Neoplasm Metastasis
63
Pancreatic Neoplasms
55
Ovarian Neoplasms
49
Sarcoma
45
Carcinoma, Renal Cell
45
Triple Negative Breast Neoplasms
42
Urinary Bladder Neoplasms
41
Leukemia, Lymphocytic, Chronic, B-Cell
41
Glioblastoma
41
Carcinoma, Hepatocellular
41
Recurrence
40
Head and Neck Neoplasms
37
Lymphoma, Large B-Cell, Diffuse
35
Brain Neoplasms
35
Myelodysplastic Syndromes
34
Hematologic Neoplasms
34
Precursor Cell Lymphoblastic Leukemia-Lymphoma
33
Lymphoma, Non-Hodgkin
33
Lymphoma, Mantle-Cell
32
Interventions
lentiviral minigene vaccine of COVID-19 coronavirus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Active not recruiting
×
Pathologic Complete Response
×
Clear all
NCT01686334
2024-03-12
WIDEA
University Hospital, Antwerp
Phase 2
Active not recruiting
130 enrolled